



Mark Payton - CEO, Martin Glanfield - CFO, Matt Mead - CIO

6 December 2017

## Important notice



This document has been prepared by and is the sole responsibility of Mercia Technologies (the "Company"), comprises these presentation slides for the sole use at a presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together the "Slides") concerning the Company.

The information in the Slides does not comprise an admission document, listing particulars or a prospectus relating to the Company or any subsidiary of the Company (together the "Group"), does not constitute an offer or invitation to purchase or subscribe for any securities of the Company, does not constitute or form part of a prospectus or admission document and should not be relied on in connection with a decision to purchase or subscribe for any such securities. The Slides and the accompanying verbal presentation do not constitute a recommendation regarding any decision to sell or purchase securities in the Company.

The Slides are confidential and the Slides are being supplied to you solely for your information and may not without the Company's consent be reproduced, distributed or otherwise disclosed to any other person or published, in whole or in part, for any purpose. No reliance may be placed for any purpose whatsoever on the information contained in the Slides or the completeness or accuracy of such information. No representation or warranty, express or implied, is given by or on behalf of the Company or their respective shareholders, directors, members, officers, employees, agents, affiliates representative or advisers or any other person as to the accuracy, completeness or fairness of the information or opinions contained in the slides, and no liability is accepted for any such information or opinions (including in the case of negligence, but excluding any liability for fraud). In addition, no duty of care or otherwise is owed by any such person to recipients of the Slides or any other person in relation to the Slides. The information set out in the Slides is subject to updating, completion, revision, verification and amendment, and such information may change materially.

Nothing in the Presentation is, or should be relied on as, a promise or representation as to the future. The Slides may contain forward-looking statements, which relate, inter alia, to the Group's proposed strategy, plans and objectives. Forward-looking statements are sometimes identified by the use of terminology such as "believes", "expects", "may", "will", "could", "should" "shall", "risk", "intends", "estimates", "aims", "predicts", "continues", "assumes", "positions" or "anticipates" or the negatives thereof, other variations thereon or comparable terminology. By its very nature, such forward looking information requires the Group to make assumptions that may or may not materialise. Such forward-looking statements may be price sensitive and involve known and unknown risks, uncertainties and other important factors beyond the control of the Group that could cause the actual performance or achievements of the Company to be materially different from such forward-looking statements. Past performance of the Group cannot be relied upon as a guide to future performance. Accordingly, you should not rely on any forward-looking statements and the Group accepts no obligation to disseminate any updates or revisions to such forward-looking statements. No representations or warranties of any kind are made by any person as to the accuracy of such statements, estimates or projections, or that any of the events expressed or implied in any such statements, estimates or projections will actually occur. The Company is not under any obligation, and expressly disclaims any intention, to update or revise any such statements, estimates or projections. No statement in the Slides is intended as a profit forecast or a profit estimate and no statement in the Slides or accompanying verbal presentation should be interpreted as a to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue relia

This presentation has not been verified. The tables presented in the Slides have been produced using spreadsheets and may be subject to rounding differences.

The Slides do not constitute or form part of an offer or invitation to issue or sell, or the solicitation of an offer to subscribe or purchase, any securities to any person in any jurisdiction.

Cenkos Securities plc, who is authorised and regulated by the Financial Conduct Authority, has been appointed the Company's Nominated Adviser and will not be responsible to anyone other than the Company for providing the protections afforded to customers of Cenkos Securities plc. Any other person should seek their own independent legal, investment and tax advice as they see fit. Cenkos Securities plc's responsibilities as the Company's Nominated Adviser under the AIM Rules will be owed solely to the London Stock Exchange plc and not to the Company, to any of its directors or any other person in respect of a decision to subscribe for or acquire shares or other securities in the Company. Cenkos Securities plc have not authorised the contents of, or any part of, the Slides and no representation or warranty, express or implied, is made as to any of its contents.

Terms and conditions relating to the Slides and the presentation and any matter or dispute (whether contractual or non-contractual) arising out of them shall be governed by and construed in accordance with English law and the English Courts shall have exclusive jurisdiction in relation to any such matter or dispute.

By attending the presentation of the Slides and/or accepting this document you agree to be bound by the foregoing limitations and restrictions and, in particular, will be taken to have represented, warranted and undertaken that: (i) you have read and agree to comply with the contents of this notice; (ii) you will observe the foregoing provisions, limitations and conditions; and (iii) you will not forward the Slides (including any information given in the verbal presentation of the Slides) to any other person, or reproduce or publish this document, in whole or in part, for any purpose.

## The Board and Investment Team





Dr Mark Payton CEO



Martin Glanfield CFO



Matt Mead



Jonathan Diggines Third Party Funds



Susan Searle Non-executive Chair



lan Metcalfe Snr Independent Director



Ray Chamberlain Non-executive Director



Julian Viggars Head of Technology, Third Party Funds



Mike Hayes Head of Digital & Digital Entertainment



Peter Dines
Head of Life Sciences
& Biosciences



Dr Alistair Forbes Head of Software & the Internet



Dr Mark Volanthen Head of Electronics, Materials & Engineering/ Manufacturing



Dr Nicola Broughton Head of University Technology Transfer

## Progress since IPO





#### January 2007 Mercia established



# December 2014 IPO: £70.0m raised

- 11 direct investments; 20% MF2
- £9.0m book value
- 1 office in the Midlands
- Circa £20.0m in managed funds
- 9 university partnerships



#### March 2016 Enterprise Ventures acquisition

- Consideration of up to £11.0m
- Enlarged pipeline of Emerging Stars
- Four new offices; 32 experienced staff
- Immediately earnings enhancing



# December 2016 Sale of Allinea Software to ARM

- First cash exit, with 88% uplift on Mercia Technologies' investment cost



#### September 2016 H1 2017

- 26 direct investments
- £46.6m book value
- Circa 60 employees



#### July 2016 First IPO

- Concepta IPO on AIM



#### March 2016 FY 2016

- 22 direct investments
- £38.1m book value
- 6 offices
- Circa £220.0m in managed funds
- 18 university partnerships



#### January 2017 Fundraise: £40.0m



## February 2017 Fund wins

- £108.5m fund mandate wins
- Managing two of BBB's Northern Powerhouse Investment Funds
- Total FUM reaches £336.5m



#### March 2017 FY 2017

- 26 direct investments
- £52.0m book value
- Circa £336.5m in managed funds
- Net assets £121.4m
- Pre-exceptional operating profit of £1.9m
- Unrestricted cash of £59.6m

## Mercia's Progress; H1 2017/18 against H1 2016/17



Revenue up 66% to £4.8m

Net expenses down 40% to £0.9m

Pre-exceptional operating profit up 80% to £1.8m

Portfolio value up 24% to £64.7m

Fair value gains £3.0m

NAV per share 41.1p - up 7.9%

Unrestricted cash up 103% to £48.6m

FUM up 53% to £336.5m University partners
19

# University partnerships delivering value



## The Midlands













Scotland

















Delivering 50 innovative opportunities













## The North



UNIVERSITY OF LEICESTER










# Complete Capital Solution






# Managed funds delivering value



allin∈a	blueprism			
<ul> <li>MF1, MF2, PLC balance sheet</li> <li>First fund investment - 2009</li> <li>University of Warwick</li> <li>Total invested - £0.8m</li> <li>Fund return - 26x</li> <li>PLC return - 88% on invested cost</li> </ul>	<ul> <li>RisingStars Growth Fund I</li> <li>First fund investment - 2004</li> <li>Investment Team networks</li> <li>Total invested - £0.9m</li> <li>Return to date - 55x</li> <li>Market Cap - c£0.9bn</li> <li>Remaining fund stake - 4.9%</li> <li>Performance fee/carried interest to PLC</li> </ul>			



## Focused



### Software & the Internet

- Artificial intelligence
- Cybersecurity
- Software as a service
- Analytical tools
- Adtech



#### Digital & Digital Entertainment

- Virtual reality
- Augmented reality
- Mixed reality
- Serious games



### Life Sciences & Biosciences

- Diagnostics
- Digital health
- Medical devices




# Electronics, Materials & Manufacturing/Engineering

- Energy
- Communications
- High value electronics
- Manufacturing applications



## Portfolio Composition







# Software & the Internet



Dr Alistair Forbes – Sector Head 15+ years in the sector

Co-founder of HoundDog Technology, acquired by GFI Software in 2009. He then held the position of GM for a division that grew from \$6.0m ARR to \$100.0m ARR in a period of 6 years







CROWDREACTIVE

## Intechnica

Science Warehouse Intelligent Positioning

**Crowd Reactive** 

Intechnica

Equity stake: 62.6%

Equity stake: 26.7%

Equity stake: 28.3%

Equity stake: 5.1%

Holding value: £9.9million

Holding value: £2.5million

Holding value: £1.5million

Holding value: £0.3million





# Digital & Digital Entertainment

Investment Director

Mike Hayes – Sector Head 20+ years in the sector

Formerly CEO at SEGA Europe & America, sales & marketing director at Nintendo and marketing director at Codemasters











**nDreams** 

Edge Case Games

VirtTrade

Soccer Manager

Equity stake: 45.6%

Equity stake: 21.2%

Equity stake: 28.4%

Equity stake: 31.6%

Holding value: £13.0million

Holding value: £3.1million

Holding value: £2.3million

Holding value: £1.6million





Electronics,
Materials &
Manufacturing/
Engineering



Dr Mark Volanthen – Sector Head 20+ years in the sector

Named on 65 patents. Founding employee at Kymata, acquired by Alcatel for \$118.0million











Warwick Audio Technologies

Impression Technologies Smart Antenna Technologies

Faradion

Equity stake: 64.0%

Equity stake: 26.4%

Equity stake: 28.2%

Equity stake: 13.6%

Holding value: £6.2million

Holding value: £3.1million

Holding value: £2.3million

Holding value: £1.3million





Life Sciences & Biosciences



Peter Dines – Sector Head 20+ years in the sector

Former MD of Surgicraft, during which time sales tripled, sold to Livingbridge











Oxford Genetics

Concepta

The Native Antigen Company

Medherant

Equity stake: 40.6%

Equity stake: 18.2%

Equity stake: 32.7%


Equity stake: 11.3%

Holding value: £7.0million

Holding value: £2.1million

Holding value: £1.9million

Holding value: £0.7million





# Summary financial information



	Six months to 30 Sept. 2017 £'000	Six months to 30 Sept. 2016 £'000	Year to 31 March 2017 £'000					
Income statement - key items								
Revenue	4,849	2,887	6,660					
Cost of sales and other administrative expenses	(5,697)	(4,341)	(9,143)					
Net expenses	(848)	(1,454)	(2,483)					
Fair value movements in investments	3,033	2,807	4,268					
Realised gains on disposal of investments	-	-	839					
Exceptional item	(562)	-	(1,125)					
Profit for the financial period/year	1,431	1,134	1,043					
Balance sheet – key items								
Direct investment portfolio value	64,740	46,616	52,028					
Cash and short-term liquidity investments *	55,167	24,011	63,829					
Net assets	123,581	81,341	121,354					
Cash flow – key item								
Net cash flows from direct investment activities	(9,679)	(5,666)	(8,779)					

<sup>\*</sup>includes £6.6m of cash held on behalf of MFM third-party fund investors (30:09:16 £nil; 31:03:17 £4.2m)

# Direct investment holdings: H1 2017/18




	Net investment value As at 1 April 2017	Net cash invested Six months to 30 September 2017	Fair value movement Six months to 30 September 2017	Net investment value As at 30 September 2017	Percentage held As at 30 September 2017
Investment	£'000	£'000	£'000	£'000	%
nDreams Ltd	10,979	2,000	-	12,979	45.6
Science Warehouse Ltd	9,913	-	-	9,913	62.6
Oxford Genetics Ltd	2,196	2,500	2,315	7,011	40.6
Warwick Audio Technologies Ltd	2,791	1,800	1,560	6,151	64.0
Impression Technologies Ltd	1,500	1,500	80	3,080	26.4
Edge Case Games Ltd	2,310	750	-	3,060	21.2
Ton UK Ltd t/a Intelligent Positioning	2,500	-	-	2,500	26.7
PsiOxus Therapeutics Ltd	2,377	-	-	2,377	1.5
VirtTrade Ltd	1,538	750	-	2,288	28.4
Smart Antenna Technologies Ltd	2,259	-	-	2,259	28.2
Concepta plc	3,400	-	(1,275)	2,125	18.2
The Native Antigen Company Ltd	1,141	22	731	1,894	32.7
LM Technologies Ltd	1,770	-	-	1,770	41.4
Soccer Manager Ltd	1,599	-	-	1,599	31.6
Crowd Reactive Ltd	1,500	-	-	1,500	28.3
sureCore Ltd	1,500	-	-	1,500	23.0
Faradion Ltd	1,299	-	-	1,299	13.6
Medherant Ltd	650	-	-	650	11.3
Other direct investments	806	357	(378)	785	n/a
Totals	52,028	9,679	3,033	64,740	n/a

99% of portfolio value represented by top 18 investments

# Valuation policy and portfolio summary



- All £64.7million of investments are held at fair values based on IPEVCV Guidelines
- Early stage companies often have no current/short-term future earnings or positive cash flows
- Consequently, the most appropriate fair value methodology is that based on available market data, being the 'price of recent investment'
- 'Price of recent investment' can be either 'price of recent funding round' or 'cost' in the case of a new direct investment



# Strategy for continued growth





## NAV growth

Strong focus on the accelerated growth in the value of direct investments



# Minimisation of NAV erosion

Revenue growth rate greater than cost base increase




## Leverage partnerships

We only invest from our managed funds into which we have strong deal flow from university partnerships and personal networks, from one of the largest capital deployment teams in the UK




#### Realise value

Through trade sales and IPOs, leading to the recycling/return of capital



# Movements in portfolio: IPO to H1 2017/18





# Movements in portfolio: H1 2017/18





- Valuation as at 1 April 2017
- Net investments made during the period
- Unrealised gains on the revaluation of investments
- Unrealised losses on the revaluation of investments
- Valuation as at 30 September 2017


## Movements in net assets: IPO to H1 2017/18






# Movements in net assets: H1 2017/18









- **6** 0330 223 1430
- info@merciatech.co.uk
- www.merciatech.co.uk